These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 33787221)

  • 21. Genome-wide bioinformatics analysis of human protease capacity for proteolytic cleavage of the SARS-CoV-2 spike glycoprotein.
    Matveev EV; Ponomarev GV; Kazanov MD
    Microbiol Spectr; 2024 Feb; 12(2):e0353023. PubMed ID: 38189333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
    Paull JRA; Heery GP; Bobardt MD; Castellarnau A; Luscombe CA; Fairley JK; Gallay PA
    Antiviral Res; 2021 Jul; 191():105089. PubMed ID: 34010661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
    Prabhakara C; Godbole R; Sil P; Jahnavi S; Gulzar SE; van Zanten TS; Sheth D; Subhash N; Chandra A; Shivaraj A; Panikulam P; U I; Nuthakki VK; Puthiyapurayil TP; Ahmed R; Najar AH; Lingamallu SM; Das S; Mahajan B; Vemula P; Bharate SB; Singh PP; Vishwakarma R; Guha A; Sundaramurthy V; Mayor S
    PLoS Pathog; 2021 Jul; 17(7):e1009706. PubMed ID: 34252168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site.
    Mykytyn AZ; Breugem TI; Riesebosch S; Schipper D; van den Doel PB; Rottier RJ; Lamers MM; Haagmans BL
    Elife; 2021 Jan; 10():. PubMed ID: 33393462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
    Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
    Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Snake venom phospholipase A
    Siniavin AE; Streltsova MA; Nikiforova MA; Kudryavtsev DS; Grinkina SD; Gushchin VA; Mozhaeva VA; Starkov VG; Osipov AV; Lummis SCR; Tsetlin VI; Utkin YN
    Cell Mol Life Sci; 2021 Dec; 78(23):7777-7794. PubMed ID: 34714362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein.
    Shuster A; Pechalrieu D; Jackson CB; Abegg D; Choe H; Adibekian A
    ACS Chem Biol; 2021 Dec; 16(12):2845-2851. PubMed ID: 34792325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.
    Shah PP; Wang T; Kaletsky RL; Myers MC; Purvis JE; Jing H; Huryn DM; Greenbaum DC; Smith AB; Bates P; Diamond SL
    Mol Pharmacol; 2010 Aug; 78(2):319-24. PubMed ID: 20466822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
    Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
    Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
    J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
    Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
    Padmanabhan P; Desikan R; Dixit NM
    PLoS Comput Biol; 2020 Dec; 16(12):e1008461. PubMed ID: 33290397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.